Initial Therapy With Merck' JANUMET To Provide Greater Blood Sugar Lowering
Data pooled from 104 weeks of studies showed sustained results for over two years
Merck has presented new data at the American Diabetes Association (ADA') 69th Annual Scientific Sessions. It showed that initial treatment with JANUMET (sitagliptin/metformin) provided greater blood sugar improvements in drug naive patients with type 2 diabetes, as compared with metformin alone.
In separate post-hoc analysis, data pooled from 104 weeks of studies showed that JANUVIA (sitagliptin), when taken alone (two studies) or in combination with metformin (two studies), provided significant blood sugar lowering, which was sustained over two years.
Barry Goldstein, Vice President of Clinical Research, Diabetes and Obesity at Merck, said: In this study, initial combination therapy with the fixed-dose combination JANUMET for the treatment of type 2 diabetes helped patients achieve blood sugar goals more effectively than metformin alone. For physicians who treat patients who need to lower their blood sugar levels, this may be useful information.
Related Insight
Suppliers Directory
A-Consult - Professional Regulatory Affairs and Drug Safety Services
A-consult offers professional assistance to the pharmaceutical industry within all areas of Regulatory Affairs and Drug Safety.
Suppliers
Pharmnet - Contract Research Organisation
Pharmnet is an independent CRO located in Prague, Czech Republic. Founded in 1994, it is currently a leading Czech clinical research organisation with a record of 180 Phase II-III clinical studies monitored in the Czech Republic and other CEE countries.
Suppliers
Almac - Integrated Drug Development Solutions
Almac offers an unparalleled range of drug development solutions to over 600 customers worldwide, including all the world leaders in the pharmaceutical and biotechnology sectors.
Suppliers
AR2i - Liquid Handling, Laboratory Material and Technology, Aparatus, Automation and Glassware
AR2i is a leading research laboratory dedicated to analytical methods and quality control of pharmaceuticals, parapharmaceuticals and some cosmetic products, on behalf of laboratories and consulting companies.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
A New Approach to Outsourced Drug Development
Published by INC Research
White Papers
Make time for science with the Rocket
Published by Genevac
White Papers
Pharmacovigilance Services
Published by DOKUMEDS
White Papers
Performance Management in Medical Affairs
Published by Kinapse
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.